Aripiprazole

Generic Name: Aripiprazole

Brand Names: Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₇Cl_₂N_₃O_₂

CAS Number: 129722-12-9

Unique Ingredient Identifier: 82VFR53I78

Background: Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors. Aripiprazole was given FDA approval on November 15, 2002.

Indication: Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar mania. Finally, an extended-release, bimonthly injection formulation of aripiprazole is indicated for the treatment of adult schizophrenia and maintenance therapy for adult bipolar I disorder.

Associated Conditions: Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode

Associated Therapies: Monotherapy

Clinical Trials

Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia

Interventions: Drug: Olanzapine
Drug: Perphenazine
Drug: Aripiprazole
Drug: Metformin
Drug: Simvastatin
Drug: Benztropine

First Posted Date: 2008-12-04

Last Posted Date: 2013-02-08

Lead Sponsor: National Institute of Mental Health (NIMH)

Target Recruit Count: 21

Registration Number: NCT00802100

Locations: 🇺🇸
Medical College of Georgia, Augusta, Georgia, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
SHANTI Clinical Trials, Colton, California, United States

and more 10 locations

Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder

Not Applicable

Terminated

Conditions: Bipolar Disorder

Interventions: Drug: aripiprazole
Drug: risperidone

First Posted Date: 2008-09-03

Last Posted Date: 2020-01-06

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 5

Registration Number: NCT00746252

Locations: 🇺🇸
University of Maryland, School of Medicine, Department of Psychiatry, Division of Child and Adolescent Psychiatry, Baltimore, Maryland, United States

A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence

Phase 2

Conditions: Schizophrenia
Cocaine Dependence

Interventions: Drug: Aripiprazole
Drug: Perphenazine

First Posted Date: 2008-08-18

Last Posted Date: 2012-09-07

Lead Sponsor: Paul Saenger

Target Recruit Count: 44

Registration Number: NCT00737256

Locations: 🇺🇸
Veteran's Affairs Medical Center, Denver, Colorado, United States

Aripiprazole for Methamphetamine Dependence: Double Blind Placebo Trial

Phase 4

Withdrawn

Conditions: Methamphetamine Dependence

Interventions: Drug: Placebo
Drug: Aripiprazole

First Posted Date: 2008-08-05

Last Posted Date: 2015-06-26

Lead Sponsor: US Department of Veterans Affairs

Registration Number: NCT00728312

Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Aripiprazole
Drug: Olanzapine

First Posted Date: 2008-07-10

Last Posted Date: 2013-11-08

Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Target Recruit Count: 690

Registration Number: NCT00712686

Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia

Phase 4

Terminated

Conditions: Schizophrenia

Interventions: Drug: Aripiprazole
Drug: Risperidone

First Posted Date: 2008-07-09

Last Posted Date: 2020-07-28

Lead Sponsor: Kettering Health Network

Target Recruit Count: 21

Registration Number: NCT00712270

Locations: 🇺🇸
Wallace Kettering Neuroscience Institute, Kettering, Ohio, United States

Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder

Phase 3

Completed

Conditions: Chronic Motor or Vocal Tic Disorder
Tourette's Disorder

Interventions: Drug: placebo
Drug: aripiprazole

First Posted Date: 2008-06-27

Last Posted Date: 2013-07-26

Lead Sponsor: Korea Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 61

Registration Number: NCT00706589

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷
Inha University Hospital, Inchon, Korea, Republic of
🇰🇷
Yonsei University Severance Hospital, Seoul, Korea, Republic of

and more 3 locations